These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 15380603)
1. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. DeWyngaert JK; Noz ME; Ellerin B; Kramer EL; Maguire GQ; Zeleznik MP Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):654-62. PubMed ID: 15380603 [TBL] [Abstract][Full Text] [Related]
2. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy. Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816 [TBL] [Abstract][Full Text] [Related]
3. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050 [TBL] [Abstract][Full Text] [Related]
4. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696 [TBL] [Abstract][Full Text] [Related]
6. Progress in SPECT/CT imaging of prostate cancer. Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563 [TBL] [Abstract][Full Text] [Related]
7. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure. Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445 [TBL] [Abstract][Full Text] [Related]
8. Enhancing the utility of prostascint SPECT scans for patient management. Noz ME; Chung G; Lee BY; Maguire GQ; DeWyngaert JK; Doshi JV; Kramer EL; Murphy-Walcott AD; Zeleznik MP; Kwak NG J Med Syst; 2006 Apr; 30(2):123-32. PubMed ID: 16705997 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236 [TBL] [Abstract][Full Text] [Related]
10. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Sodee DB; Sodee AE; Bakale G Semin Nucl Med; 2007 Jan; 37(1):17-28. PubMed ID: 17161036 [TBL] [Abstract][Full Text] [Related]
11. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Sodee DB; Ellis RJ; Samuels MA; Spirnak JP; Poole WF; Riester C; Martanovic DM; Stonecipher R; Bellon EM Prostate; 1998 Nov; 37(3):140-8. PubMed ID: 9792131 [TBL] [Abstract][Full Text] [Related]
14. Bone metastases from poorly differentiated adenocarcinoma of the prostate diagnosed by In-111 ProstaScint (Capromab Pendetide) images with negative results of Tc-99m MDP bone scan and without significant elevation of prostate-specific antigen. Norris S; Halkar R; Galt J; Petros J; Keller J Clin Nucl Med; 1999 Nov; 24(11):905-7. PubMed ID: 10551485 [No Abstract] [Full Text] [Related]
15. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. Chen L; Price RA; Wang L; Li J; Qin L; McNeeley S; Ma CM; Freedman GM; Pollack A Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):636-47. PubMed ID: 15380601 [TBL] [Abstract][Full Text] [Related]
16. Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. Smitsmans MH; Wolthaus JW; Artignan X; de Bois J; Jaffray DA; Lebesque JV; van Herk M Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):623-35. PubMed ID: 15380600 [TBL] [Abstract][Full Text] [Related]
17. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. Smitsmans MH; de Bois J; Sonke JJ; Betgen A; Zijp LJ; Jaffray DA; Lebesque JV; van Herk M Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):975-84. PubMed ID: 16253772 [TBL] [Abstract][Full Text] [Related]
18. Delineation of target volume for radiotherapy of high-grade gliomas by 99m Tc-MIBI SPECT and MRI fusion. Krengli M; Loi G; Sacchetti G; Manfredda I; Gambaro G; Brambilla M; Carriero A; Inglese E Strahlenther Onkol; 2007 Dec; 183(12):689-94. PubMed ID: 18040614 [TBL] [Abstract][Full Text] [Related]
19. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. Wilkinson S; Chodak G J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753 [TBL] [Abstract][Full Text] [Related]
20. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]